Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

DCC to sell UK & Ireland Info Tech business to Aurelius for £100m

(Sharecast News) - Sales, marketing and support services group DCC said on Monday that it has agreed to sell its Info Tech business in the UK and Ireland to private equity investor Aurelius for around £100m. In the year ending 31 March 2025, the business recorded revenue of £2bn and represented approximately 1% of DCC's continuing operating profit.

DCC said the net cash proceeds from the sale are "not material", reflecting the working capital seasonality and the supply chain financing associated with the business.

It also said it retains freehold title of its UK national distribution centre in Burnley, England.

DCC noted that the remainder of DCC Technology, its Pro Tech business, is principally based in North America, with a smaller growth platform in Europe.

Chief executive Donal Murphy said: "The divestment of Info Tech in the UK and Ireland is a further material step in simplifying our group and focusing on our high growth, high return, energy business. It follows the sale of DCC Healthcare announced in April 2025.

"We have made huge strategic progress this year. We are confident that Aurelius will be a strong partner for our UK and Ireland Info Tech business, driving further operational and financial improvement. This transaction also represents a positive move for our team, providing new opportunities for growth, development, and long-term success."

At 0940 BST, the shares were down 1.4% at 4,666.80p.

Dan Coatsworth, investment analyst at AJ Bell, said: "Support services outfit DCC saw shareholders react with some mild disappointment to news it will receive no meaningful proceeds from the sale of its technology distribution business.

"The transaction does move along the tidying-up process as the business looks to sharpen its focus on energy - its highest returning area of operation."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.